Rare protein sequence variation in SV2A gene does not affect response to levetiracetam

Simple item page
dc.contributor.authorDibbens, L.
dc.contributor.authorHodgson, B.
dc.contributor.authorHelbig, K.
dc.contributor.authorOliver, K.
dc.contributor.authorMulley, J.
dc.contributor.authorBerkovic, S.
dc.contributor.authorScheffer, I.
dc.date.issued2012
dc.description.abstractLevetiracetam, a broad spectrum antiepileptic drug, binds to membrane protein SV2A. The protein coding region of SV2A was sequenced in 158 patients with focal or generalized epilepsies divided into three groups based on their response to levetiracetam: responders (>75% decrease), exacerbators (50% increase) and non-responders. Nonsynonymous coding variation within SV2A was extremely rare, suggesting that rare variation is not likely to account for the individual differences in response to levetiracetam.
dc.description.statementofresponsibilityLeanne M. Dibbens, Bree L. Hodgson, Katherine L. Helbig, Karen L. Oliver, John C. Mulley, Samuel F. Berkovic, Ingrid E. Scheffer
dc.identifier.citationEpilepsy Research, 2012; 101(3):277-279
dc.identifier.doi10.1016/j.eplepsyres.2012.04.007
dc.identifier.issn0920-1211
dc.identifier.issn1872-6844
dc.identifier.urihttp://hdl.handle.net/2440/73561
dc.language.isoen
dc.publisherElsevier Science BV
dc.rights© 2012 Elsevier B.V. All rights reserved.
dc.source.urihttps://doi.org/10.1016/j.eplepsyres.2012.04.007
dc.subjectSV2A
dc.subjectLevetiracetam
dc.subjectEpilepsy
dc.subjectGenetics
dc.subjectPharmacogenetics
dc.titleRare protein sequence variation in SV2A gene does not affect response to levetiracetam
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Paediatrics publications